Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,597 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery.
Kono M, Kumai T, Hayashi R, Yamaki H, Komatsuda H, Wakisaka R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Kobayashi H, Harabuchi Y. Kono M, et al. Among authors: hayashi r, hayashi t. Cancer Immunol Immunother. 2021 Dec;70(12):3421-3434. doi: 10.1007/s00262-021-02940-5. Epub 2021 Apr 18. Cancer Immunol Immunother. 2021. PMID: 33866408 Free PMC article.
Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma.
Nagato T, Ueda S, Takahara M, Kishibe K, Komabayashi Y, Kumai T, Ohara K, Hirata-Nozaki Y, Harabuchi S, Hayashi R, Ohkuri T, Bernasconi M, Nadal D, Kobayashi H, Harabuchi Y. Nagato T, et al. Among authors: hayashi r. Lab Invest. 2019 May;99(5):612-624. doi: 10.1038/s41374-018-0182-9. Epub 2019 Jan 21. Lab Invest. 2019. PMID: 30664711 Free article.
Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma.
Harabuchi S, Kosaka A, Yajima Y, Nagata M, Hayashi R, Kumai T, Ohara K, Nagato T, Oikawa K, Ohara M, Harabuchi Y, Ohkuri T, Kobayashi H. Harabuchi S, et al. Among authors: hayashi r. Biochem Biophys Res Commun. 2020 Feb 5;522(2):408-414. doi: 10.1016/j.bbrc.2019.11.107. Epub 2019 Nov 23. Biochem Biophys Res Commun. 2020. PMID: 31771883
Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer.
Ohara M, Ohara K, Kumai T, Ohkuri T, Nagato T, Hirata-Nozaki Y, Kosaka A, Nagata M, Hayashi R, Harabuchi S, Yajima Y, Oikawa K, Harabuchi Y, Sumi Y, Furukawa H, Kobayashi H. Ohara M, et al. Among authors: hayashi r. Cancer Immunol Immunother. 2020 Jun;69(6):989-999. doi: 10.1007/s00262-020-02524-9. Epub 2020 Feb 21. Cancer Immunol Immunother. 2020. PMID: 32086539 Free PMC article.
Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.
Hayashi R, Nagato T, Kumai T, Ohara K, Ohara M, Ohkuri T, Hirata-Nozaki Y, Harabuchi S, Kosaka A, Nagata M, Yajima Y, Yasuda S, Oikawa K, Kono M, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Harabuchi Y, Kobayashi H. Hayashi R, et al. Among authors: hayashi t. Oncoimmunology. 2020 Dec 29;10(1):1856545. doi: 10.1080/2162402X.2020.1856545. Oncoimmunology. 2020. PMID: 33457076 Free PMC article.
A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
Nagata M, Kosaka A, Yajima Y, Yasuda S, Ohara M, Ohara K, Harabuchi S, Hayashi R, Funakoshi H, Ueda J, Kumai T, Nagato T, Oikawa K, Harabuchi Y, Esteban C, Ohkuri T, Kobayashi H. Nagata M, et al. Among authors: hayashi r. Cancer Immunol Immunother. 2021 Aug;70(8):2301-2312. doi: 10.1007/s00262-021-02864-0. Epub 2021 Jan 28. Cancer Immunol Immunother. 2021. PMID: 33507344 Free PMC article.
The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer.
Okazaki S, Sasaki T, Yasuda S, Abe M, Yoshida N, Yoshida R, Ishibashi K, Minami Y, Okumura S, Chiba S, Takei H, Hayashi R, Nagato T, Kobayashi H, Sugitani A, Ono Y, Mizukami Y, Kitada M, Ohsaki Y. Okazaki S, et al. Among authors: hayashi r. Oncol Lett. 2021 May;21(5):420. doi: 10.3892/ol.2021.12681. Epub 2021 Mar 28. Oncol Lett. 2021. PMID: 33841581 Free PMC article.
A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy.
Kosaka A, Yajima Y, Hatayama M, Ikuta K, Sasaki T, Hirai N, Yasuda S, Nagata M, Hayashi R, Harabuchi S, Ohara K, Ohara M, Kumai T, Ishibashi K, Hirata-Nozaki Y, Nagato T, Oikawa K, Harabuchi Y, Celis E, Okumura T, Ohsaki Y, Kobayashi H, Ohkuri T. Kosaka A, et al. Among authors: hayashi r. Cancer Sci. 2021 Jul;112(7):2705-2713. doi: 10.1111/cas.14973. Epub 2021 Jun 3. Cancer Sci. 2021. PMID: 34009705 Free PMC article.
CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes.
Kosaka A, Ishibashi K, Nagato T, Kitamura H, Fujiwara Y, Yasuda S, Nagata M, Harabuchi S, Hayashi R, Yajima Y, Ohara K, Kumai T, Aoki N, Komohara Y, Oikawa K, Harabuchi Y, Kitada M, Kobayashi H, Ohkuri T. Kosaka A, et al. Among authors: hayashi r. J Exp Med. 2021 Nov 1;218(11):e20200792. doi: 10.1084/jem.20200792. Epub 2021 Sep 24. J Exp Med. 2021. PMID: 34559187 Free PMC article.
1,597 results